Pharma News

The Central Drugs Standard Control Organisation along with state licensing authorities has conducted risk-based inspections of 162 pharmaceutical firms and issued show-cause notices in 143 cases, Union Health minister Mansukh Mandaviya said on Tuesday.

IIHMR University, Jaipur, organised an Inauguration ceremony of newly admitted students of MBA (Hospital and Health Management), MBA (Pharmaceutical Management) and MBA (Development Management) programmes, 2023-25, at its campus.

Central Drugs Standard Control Organization (CDSCO) has issued show- cause notices to various firms engaged in online/internet sale of Drugs on 8th & 9th February 2023.

The firms have mostly responded by stating that they are only providing an online platform for facilitating the sale of pharmaceutical products to customers and the platform operates solely as intermediaries, connecting the users and the licensed pharmacies.

Eli Lilly and Company announced the successful completion of its acquisition of DICE Therapeutics, Inc  The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology.

Union Minister for Science & Technology Dr Jitendra Singh said here today that "Anusandhan National Research Foundation" will define the stature of India at 2047. Replying to the discussion on "Anusandhan National Research Foundation (NRF) Bill, 2023" in the Rajya Sabha, Dr Jitendra Singh said, the Anusandhan Act will pave the way for India to join the select league of developed nations.

Intas launches of Topical TOFATAS – a DCGI-approved, Tofacitinib Ointment 2% w/w for the treatment of mild to moderate Atopic Dermatitis (AD) in patients 18 years and above having flare-ups of the disease.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The National Institutes of Health launched and is opening enrollment for phase 2 clinical trials that will evaluate at least four potential treatments for long COVID, with additional clinical trials to test at least seven more treatments expected in the coming months. Treatments will include drugs, biologics, medical devices and other therapies. The trials are designed to evaluate multiple treatments simultaneously to identify more swiftly those that are effective.

Merck known as MSD outside of the United States and Canada, announced that the pivotal Phase 3 KEYNOTE-756 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met one of its dual primary endpoints of pathological complete response (pCR) rate following the neoadjuvant part of the neoadjuvant/adjuvant study regimen in patients with high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.

Glenmark Pharmaceuticals Ltd. is an integrated, research‐led, global pharmaceutical company, with a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology.